Bare metal stents (BMS), drug-coated balloons (DCB), and drug-eluting stents (DES) are associated with lower target lesion revascularization (TLR) probabilities than percutaneous transluminal angioplasty (PTA), but the economic impact is unknown. Our objective was to study the economic impact on payers and providers of the four main endovascular strategies for the treatment of infrainguinal peripheral artery disease.
